Growth hormone regulates osteogenic marker mRNA expression in human periodontal fibroblasts and alveolar bone‐derived cells

Haase, H. R.; Ivanovski, Sašo; Waters, M. J.; Bartold, P. Mark

doi:10.1034/j.1600-0765.2003.00655.x

Cited by 62 publications

(37 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Likewise, other studies have demonstrated no improvement in BMD with GH treatment although there has been an increase in terms of osteoid, mineralizing, and eroded surfaces without any change in adjusted apposition rate, mineral apposition rate, and bone formation rate consistent with a delay or lengthened remodeling period with a possible delay in mineralization (50)(51)(52). Furthermore, in vitro data indicate that while long-term GH appears to promote mineralization, short-term treatment does not promote proliferation of osteoblast precursors or induce expression of late osteogenic markers (53).…”

Section: Controlmentioning

confidence: 88%

Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency

Conway

Szarras‐Czapnik

Rácz

et al. 2009

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Discontinuation of growth hormone (GH) therapy on completion of linear growth may adversely affect bone mineral density (BMD) in young adults with childhood-onset GH-deficiency (GHD). In the present study, we analyzed the impact of GH treatment on bone in young adults with GHD. Methods: BMD at the lumbar spine (L2-L4), total hip, and total body was measured at baseline and after 24 months in a cohort of young adults (18-25 years; nZ160) with severe GHD treated with GH during childhood who were randomized to GH (nZ109) or no treatment (nZ51) in a multicenter, multinational, open-label study. GH starting doses (0.2 mg/day (males), 0.4 mg/day (females)) were increased after 1 month to 0.6 mg/day (males) and 0.9 mg/day (females) and then to 1.0 mg/day (males) and 1.4 mg/day (females) at 3 months for the remainder of the study. Results: After 24 months, lumbar spine BMD had increased significantly more in GH-treated patients than in controls (6 vs 2%; estimated treatment difference; 3.5% (95% confidence interval, 1.52-5.51) P!0.001). GH also had a significant positive effect on total hip BMD (PZ0.015). Total body BMD was unchanged from baseline (PZ0.315). Conclusions: In young adults treated for childhood-onset GHD, there is a beneficial effect of continued GH treatment on BMD in adult life. Twenty-four months of GH treatment in these young adults was associated with an estimated 3.5% greater increase in BMD of the lumbar spine compared with controls.

show abstract

Section: Controlmentioning

confidence: 88%

Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency

Conway

Szarras‐Czapnik

Rácz

et al. 2009

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…OCN is regarded as the most specific matrix protein produced by osteoblasts during the onset of matrix mineralization as it binds hydroxyapatite [24, 25]. Ivanovski et al [8] reported that OPN and OCN were not detected in HGF cultured in basic medium at early stages.…”

Section: Discussionmentioning

confidence: 99%

In Vitro Osteogenic Induction Of Human Gingival Fibroblasts For Bone Regeneration

Mostafa¹,

Uludağ²,

Varkey³

et al. 2011

TODENTJ

View full text Add to dashboard Cite

Background And Objective:Periodontitis is an inflammatory disease causing bone loss, and is a primary cause of tooth loss. Gingival fibroblasts are readily available with minimal donor site morbidity and may be ideal for tissue engineering efforts in regenerating lost alveolar bone. Dexamethasone (Dex) is commonly employed for in vitro osteogenic induction of a variety of cells, but its effect on human gingival fibroblasts (HGF) is still controversial. Therefore, the aim of our study was to investigate the osteogenic differentiation of HGF following Dex treatment.Methods:Cultured HGFs were exposed to osteogenic medium containing a wide range of Dex concentrations (0.01-10 µM). The osteogenic phenotype was assessed based on changes in alkaline phosphatase (ALP) activity, the mRNA expression of selected extracellular matrix proteins critical for mineralization and the extent of extracellular mineralization (Von Kossa staining and Ca-content).Results:All assays showed a consistent and maximal osteogenic effect of Dex on HGF at 0.1 and 0.5 µM (weeks 3 and 4), as evidenced by significant osteopontin and osteocalcin expression and mineralization. Longer cultures (week 4) also yielded positive osteogenic effect of Dex at 0.01 µM. Moreover, ALP activity was significantly stimulated at 0.1 and 0.5 µM Dex initially after one week, but ALP was subsequently reduced under Dex. Higher Dex concentrations caused down regulation of osteogenic effects observed at the optimal (0.1-0.5 µM) concentrations.Conclusion:Under appropriate osteogenic conditioning, Dex treated HGFs could be a potential source of cells for cell-based therapy for periodontal bone regeneration.

show abstract

“…El cDNA obtenido se amplificó mediante qRT-PCR utilizando los primers específicos para cada gen. Los primers para ALP y Runx2 fueron tomados de la literatura (17, 28) y estandarizados. Los primers para GAPDH fueron diseñados con el programa OLIGO6 siguiendo las recomendaciones de Bustin, SA (Tabla1) (29). Adicionalmente los productos amplificados se insertaron en vectores plasmídicos (Corpogen Vector TOPO 2.1) para generar curvas standard y realizar el FosFatasa alcalina (alp) y Runx2 en cultivos celulaRes de osteoblastos estimulados con campo eléctRico análisis cuantitativo de la expresión de cada uno de los genes en estudio.…”

Section: Reacción En Cadena De La Polimerasa Con Transcriptasa Inversunclassified

Fosfatasa Alcalina (ALP) y Runx2 en cultivos celulares de osteoblastos estimulados con campo eléctrico

et al. 2012

View full text Add to dashboard Cite

ResumenEl objeto de este estudio fue identificar el estímulo eléctrico que debe aplicarse en cultivos celulares de osteoblastos (Ob) para aumentar la expresión del gen de Fosfatasa Alcalina (ALP) y el factor de transcripción Runx2. Se cultivaron Ob de la American Type Culture Collection (ATCC) Ref. CRL 11372. Los cultivos se estimularon del día cinco, cuando las células presentaron confluencia, hasta el día ocho. El estímulo aplicado a cada grupo experimental fue de 100mV, 200mV, 300mV, 400mV y 500mV respectivamente, se cultivó un grupo control no estimulado con cada grupo experimental. El campo eléctrico se generó con corriente alterna (AC) y se aplicó mediante dos placas de aluminio ubicadas de forma lateral y paralela a los frascos de cultivo de 25cm 2 . Los niveles de expresión de mRNA se midieron con la técnica quantitative reverse transcription polymerase chain reaction (qRT-PCR). Con la aplicación de campo generado con AC aumentó la expresión del factor de transcripción RunX2 en proporción directa al aumento del voltaje aplicado. La expresión del gen de ALP fue inversamente proporcional a la aplicación del estímulo y se identificó una diferencia significativa entre la presencia y ausencia del estímulo, siendo mayor en ausencia del estímulo. El campo eléctrico generó una señal que puede aumentar o disminuir la expresión de los genes que median la formación de tejido óseo. En el caso de Runx2, favoreció la diferenciación de células mesenquimales a Ob con la consecuente actividad de remodelación y formación del tejido óseo.Palabras clave: Osteoblastos, fosfatasa alcalina, estímulo eléctrico, Runx2, expresión génica Abreviaciones: *FA, Fosfatasa Alcalina*; *Ob, Osteoblastos* ALKALINE PHOSPHATASE (ALP) AND Runx2 IN CELL CULTURES STIMULATED OSTEOBLASTS ELECTRIC FIELD AbstractThe purpose of this study was to identify the electrical fields to be applied in osteoblast (Ob) cell cultures, in order to increase the expression of Alkaline Phosphatase (ALP) gene and the transcription factor Runx2. Ob cultured where from the American Type Culture Collection (ATCC) Ref CRL 11372. Cell Cultures received stimulation at day five, when they showed a confluent monolayer organization until day eight. The stimulus applied to each experimental group was 100mV, 200mV, 300mV, 400mV and 500mV respectively, a control group was cultured without stimulation. The electric field is generated

show abstract

Growth hormone regulates osteogenic marker mRNA expression in human periodontal fibroblasts and alveolar bone‐derived cells

Abstract: The response of the cells indicates that while long-term treatment with GH may promote mineralization, short-term treatment does not promote proliferation of osteoblast precursors nor induce expression of late osteogenic markers.

Cited by 62 publications

References 25 publications

Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency

Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency

In Vitro Osteogenic Induction Of Human Gingival Fibroblasts For Bone Regeneration

Fosfatasa Alcalina (ALP) y Runx2 en cultivos celulares de osteoblastos estimulados con campo eléctrico

Contact Info

Product

Resources

About